Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 11, 2014Journal of Clinical OncologyOpen Access

Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study

View Full Paper
Ask AI
Bookmark
Share

Authors

WHWedad HannaSunnybrook Health Science CentrePBPenny J. BarnesDalhousie UniversityMCMartin C. ChangUniversity of Vermont

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hanna et al. (2014) studied this question.

synapsesocial.com/papers/6a0cd38559b087b0dc625e92https://doi.org/10.1200/jco.2014.55.6092
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.1998 · 448 citations
  2. 2American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer2006 · 4,474 citations
  3. 3Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.2005 · 1,615 citations
  4. 4Breast cancer — one term, many entities?2011 · 233 citations
  5. 5Histopathologic Characteristics Predicting HER-2/neu Amplification in Breast Cancer2005 · 80 citations